CSF2RA Human Pre-designed siRNA Set A

Cat. No.: C1487281

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Visão geral

CSF2RA Human Pre-designed siRNA Set A contains three designed siRNAs for CSF2RA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components CSF2RA siRNA-1: 5 nmol (HPLC) CSF2RA siRNA-2: 5 nmol (HPLC) CSF2RA siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)

Specifications

Condições de armazenamento de armazenamento

Store at -20°C

Enviado em

Ice chest + Ice pads

Este produto requer transporte de cadeia fria. Serviços terrestres e outros serviços econômicos não estão disponíveis.

Application Protocols

General literature-based protocol for siRNA transfection and knockdown assessment (adjust per cell type and transfection reagent):

1. Preparation

• Thaw siRNA aliquots on ice; briefly spin down. Work RNase-free.
• Dilute siRNA in serum-free medium to achieve desired final concentration (e.g., 5–50 nM in wells).

2. Complex formation

• Dilute transfection reagent separately in serum-free medium per manufacturer’s instructions.
• Combine diluted siRNA and reagent; mix gently and incubate 5–20 min at room temperature to allow complexation.

3. Cell exposure

• Add complexes dropwise to cells at 50–70% confluence (adherent) or to appropriately counted suspension cells.
• After 4–6 h (if required by reagent), replace with complete medium; some reagents permit direct exposure in serum-containing media.

4. Incubation and analysis

• Harvest mRNA at 24–48 h; assess protein knockdown at 48–96 h.
• Optional: Stimulate with GM-CSF to probe functional signaling changes.

5. Controls and replication

• Include non-targeting siRNA, positive knockdown control, and mock controls. Perform biological replicates.

Note: The above represents general guidance. Specific conditions (dose, volumes, media, exposure times) should be optimized and verified with your chosen transfection system. No item-specific, validated protocol is provided.

Biological Roles

• Target gene function (CSF2RA; general biology):
  • CSF2RA encodes the alpha subunit of the granulocyte-macrophage colony-stimulating factor receptor (GM-CSF-Rα). It confers ligand-binding specificity and associates with the common beta chain (CSF2RB) for signal transduction.
  • Engagement by GM-CSF promotes survival, proliferation, and functional activation of myeloid lineage cells via JAK/STAT, MAPK, and PI3K pathways.
• Rationale for siRNA-mediated knockdown:
  • Reducing CSF2RA expression diminishes GM-CSF binding/response, enabling dissection of receptor-mediated signaling, cytokine sensitivity thresholds, and downstream transcriptional programs in human cell models.
  • Useful for probing receptor turnover, endocytosis, and crosstalk with other cytokine receptors under defined conditions.
• Model systems (examples, literature):
  • Hematopoietic cell lines, monocyte-derived macrophages, dendritic cell precursors, or epithelial models where CSF2RA is expressed.
• Readouts (general):
  • mRNA (qRT-PCR), surface receptor levels (flow cytometry), protein (immunoblot), functional outcomes such as cytokine-induced phospho-STAT activation assays.

Note: The above biological context is general literature information about CSF2RA and GM-CSF receptor signaling and is provided for research planning only. No therapeutic or diagnostic use is implied.

Buffer Applications

This product is not a buffering reagent and is not typically used to prepare buffer systems.

• For handling and storage, RNase-free water or TE buffer are commonly used vehicles (general guidance). Maintain pH near neutral (pH ~7–8) to preserve RNA integrity.
• Electrophoresis or nuclease assays, if performed as part of QC, would employ standard nucleic acid buffers (e.g., TBE/TBE-urea); these are ancillary and not specific to this item.

Refer to your transfection reagent’s documentation for any buffer-specific requirements during complex formation.

Green Alternatives

While this item is a biological oligonucleotide rather than a solvent or bulk chemical, greener practices can still be applied to its use:

• Aqueous systems:
  • Favor water or TE buffer for reconstitution and handling; avoid unnecessary organic solvents.
• Transfection reagent selection:
  • Consider biodegradable or lipid formulations with lower cytotoxicity and reduced solvent content; consult vendor data for eco-tox and disposal profiles.
• Waste minimization:
  • Scale experiments appropriately to reduce plastic consumables and chemical waste. Pool replicates within multiwell plates to minimize reagent excess.
• Energy efficiency:
  • Store at −20°C as specified; avoid ultra-low −80°C unless necessary, and batch retrievals to minimize door-open time.
• Decontamination:
  • Use RNase decontaminants with lower VOC content and follow recommended dilutions to reduce emissions.

Comparison (general):

• Conventional approach: Lipid transfection in serum-free medium using single-use plastics, frequent freeze-thaws → higher consumables/waste.
• Greener adjustments: Pre-aliquoted siRNA to avoid repeat freeze-thaw, consolidating transfections, and employing recyclable tip boxes or filtered multichannel systems where validated.

Adopt institution-approved waste and sustainability practices; maintain experimental integrity while reducing environmental footprint.

Pharmaceutical Uses

This item is supplied strictly for research use only and is not intended for human or veterinary use, clinical diagnostics, or as an active pharmaceutical ingredient.

• Formulation/excipient status: Not applicable; no pharmacopeial monograph or excipient designation is provided for this research-grade siRNA product.
• Process development (research context only):
  • Researchers may use pre-designed siRNA in discovery workflows (e.g., target validation, screening) that inform upstream R&D. Any translation to regulated settings would require separate, GMP-grade materials and comprehensive characterization not covered by this SKU.

All uses should remain within non-clinical laboratory research.

Physical Properties

Item-specific physicochemical specifications (exact MW, concentration, and sequence-dependent properties) are not provided for this SKU.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility (general, literature):
  • Highly soluble in RNase-free water and TE buffer (10 mM Tris, 0.1–1 mM EDTA, pH ~7.5–8.0)
  • Compatible with many cell culture media after complexation with transfection reagents
• pKa / logP: Not applicable in the traditional sense; siRNAs are polyanionic biopolymers with negligible partitioning into nonpolar phases.
• UV absorbance (general, literature):
  • Strong absorbance near 260 nm; extinction coefficient is sequence-dependent.
• Thermal behavior (general, literature):
  • Melting temperature (Tm) depends on length, GC content, salt concentration, and chemical modifications; duplexes are typically stable at ambient temperature in buffered solutions but should be stored cold to minimize degradation.
• Stability considerations (general):
  • Sensitive to RNases; requires RNase-free handling.
  • Lyophilized siRNA is generally more stable than solutions; aqueous solutions benefit from low-temperature storage and EDTA to chelate divalent cations.

For any item-specific values (e.g., concentration, extinction coefficient, salt form), consult the CoA/Spec Sheet.

Quality and Grades

• Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.
• What “pre-designed siRNA set” typically implies (general):
  • A curated set of siRNA duplexes designed against distinct regions of the target mRNA (here, human CSF2RA), selected using established algorithms and transcript databases to balance potency and specificity.
  • Sets may be provided as individual duplexes or as a validated pool; exact format for this SKU is not specified.
• Typical manufacturing/quality controls for research-grade siRNA (general):
  • Oligonucleotide synthesis by solid-phase methods, deprotection, desalting or HPLC/PAGE purification (method not specified for this item).
  • Verification by mass spectrometry and/or analytical HPLC (not specified for this item).
  • Endotoxin and bioburden limits may be controlled for cell-based assays (item-specific limits not specified).
• Implications for experimental use:
  • If multiple duplexes are supplied, users can screen for the most effective sequence and/or combine as a pool to mitigate off-target effects.
  • If HPLC-grade is provided, expect lower salt/adduct background and more consistent transfection outcomes, especially in sensitive primary cells.

Please consult the current CoA/Spec Sheet for the definitive purification method, pooling format, and any sequence-level QC metrics for SKU C1487281.

Reaction and Applications

This siRNA set is intended for RNA interference experiments targeting human CSF2RA.

• Primary applications:
  • Gene knockdown of CSF2RA in human cell lines or primary cells to study GM-CSF receptor signaling, receptor trafficking, and downstream transcriptional programs (e.g., JAK/STAT). No clinical or diagnostic use.
  • Pathway dissection: Evaluate effects on cytokine responsiveness, myeloid differentiation markers, or surfactant-related pathways in relevant models.
  • Assay endpoints: qRT-PCR for mRNA reduction, Western blot/flow cytometry for protein level changes, phospho-signaling assays following GM-CSF stimulation.
• Experimental design tips (general):
  • Use multiple siRNA sequences or an siRNA pool to increase likelihood of efficient knockdown and to mitigate sequence-specific off-targets.
  • Include controls: non-targeting siRNA, positive knockdown control, and transfection reagent–only control.
  • Optimize dose (commonly 5–50 nM final siRNA) and exposure time (24–96 h) per cell type; primary cells often require lower doses and gentler delivery.
  • Verify on-target effects via rescue (overexpression of siRNA-resistant CSF2RA) or orthogonal silencing (e.g., CRISPRi) when feasible.
• Transfection considerations:
  • Select delivery method suited to cell type (lipid-based, polymer-based, or electroporation). Minimize cytotoxicity while maximizing uptake.
  • Work RNase-free; prepare complexes freshly in serum-free medium and add to cells promptly.

All conditions above are general, literature-based guidance; adjust empirically for your model system.

Reaction Conditions

Not a chemical reagent for bench reactions; however, typical transfection/knockdown conditions are provided as general, literature-based guidance. Optimize empirically for cell type and transfection platform.

• Working concentration (general): Often 5–50 nM siRNA final in culture; primary cells may require lower doses.
• Complex formation:
  • Prepare siRNA–transfection reagent complexes in serum-free medium (e.g., Opti-MEM) per reagent instructions; incubate typically 5–20 min at room temperature before adding to cells.
• Cell density: Plate cells to achieve 50–70% confluence at time of transfection for adherent lines; adjust for suspension cells per reagent guidance.
• Incubation: Replace with complete medium per reagent protocol (some are serum-compatible). Assess knockdown 24–96 h post-transfection depending on mRNA/protein turnover.
• Controls: Non-targeting siRNA, positive control siRNA (known to knock down a housekeeping gene), and mock-transfected cells.
• Readouts: qRT-PCR (mRNA), Western blot/flow (protein), and functional assays (e.g., GM-CSF–induced signaling changes).

These ranges are typical literature values and are not specifications for this SKU.

Safety and Handling

• GHS classification / pictograms / H-statements: Not specified for this item; refer to SDS for authoritative information.
• Anticipated hazards (general for siRNA reagents):
  • Typically considered low hazard; may cause irritation on contact. Avoid inhalation of powders/aerosols.
  • No known combustible or peroxide-forming risks typical of organic solvents.
• PPE:
  • Lab coat, safety glasses, and appropriate gloves (e.g., nitrile). Use RNase-free, powder-free gloves to prevent RNase contamination.
• Handling:
  • Maintain RNase-free technique: dedicated tips/tubes, clean benches with RNase decontaminant, avoid touching tube rims.
  • Work on ice for prolonged manipulations in solution to limit hydrolysis.
• Incompatibilities (general):
  • Avoid RNases, strong acids/bases, and nucleases; divalent cations and elevated temperatures accelerate degradation.
  • Do not mix with oxidizing/degrading agents.
• First aid (general):
  • Skin/eye contact: Rinse with water for several minutes. Remove contaminated clothing. Seek medical attention if irritation persists.
  • Inhalation: Move to fresh air. Seek medical attention if symptoms occur.
  • Ingestion: Rinse mouth. Do not induce vomiting. Seek medical advice.
• Spill response:
  • Wipe with damp, RNase-decontaminated towels; collect waste in appropriate container. Avoid dust generation for lyophilized products.

Always consult the product-specific SDS before use.

Solvent Selection

This product is an RNA oligonucleotide reagent and is not used as an organic solvent. Solvent selection is therefore limited to dissolution and handling media.

• Primary solvents/buffers (general guidance):
  • RNase-free water for reconstitution and short-term handling
  • TE buffer (10 mM Tris-HCl, 0.1–1 mM EDTA, pH 7.5–8.0) for enhanced stability in solution
  • For transfection, dilute in serum-free medium (e.g., Opti-MEM) during complex formation with the chosen transfection reagent, then add to complete medium as per reagent guidance.
• Compatibility:
  • Incompatible with most organic solvents for biological delivery; avoid alcohols and strong denaturants except where protocol-specific (e.g., precipitation steps).
• When to choose water vs TE:
  • Use water if downstream steps are sensitive to EDTA or Tris.
  • Use TE for storage aliquots to reduce metal-catalyzed hydrolysis; verify that low EDTA does not interfere with cation-dependent assays.

For cell-based delivery, prioritize buffer systems recommended by your transfection reagent manufacturer.

Storage and Reconstitution

• Storage (from Product Data):
  • Store at −20°C.
  • Shipped in ice chest + ice pads.
• Long-term stability (general):
  • Lyophilized siRNA is typically stable for extended periods at −20°C in a dry, dark environment.
  • Aqueous solutions are best kept at −20°C in small aliquots; avoid repeated freeze–thaw cycles.
• Reconstitution (general guidance):
  • Spin down briefly before opening. Reconstitute in RNase-free water or TE buffer to a convenient stock (e.g., 10–100 µM).
  • Mix gently (no vortexing needed), allow to sit on ice for 5–10 min to fully dissolve.
  • If necessary, anneal complementary strands per supplier guidance (many sets are supplied pre-annealed; not specified for this item).
• Aliquoting:
  • Prepare single-use aliquots to prevent freeze–thaw. Store aliquots in low-adsorption, nuclease-free tubes.
• Handling:
  • Maintain RNase-free conditions. Avoid prolonged exposure at room temperature.
• Shelf life / specifications:
  • Not specified for this item; refer to CoA/Spec Sheet.

Follow institutional biosafety and nucleic acid handling practices. For definitive stability and reconstitution instructions specific to SKU C1487281, consult the product’s CoA/Spec Sheet.

Structure and Identity

This product is a pre-designed small interfering RNA (siRNA) set targeting human CSF2RA (colony stimulating factor 2 receptor alpha subunit) transcripts.

• Product type: Duplex RNA oligonucleotides (siRNA), Set A (multiple sequences pooled or provided as a panel; exact configuration not specified)
• Target gene: CSF2RA (Human)
• Intended action: RNA interference–mediated knockdown of CSF2RA mRNA
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES / InChIKey: Not applicable to heterogeneous oligonucleotide mixtures; not specified for this item.
• CAS / CID: Not specified for this item; refer to CoA/Spec Sheet.
• Typical structural features (general, literature):
  • Short ~19–21 bp RNA duplex with two-nucleotide 3′ overhangs per strand (commonly UU or dTdT; exact design not specified)
  • Phosphodiester or modified backbones; chemical modifications (e.g., 2′-O-Me, phosphorothioate) may be used in some siRNAs to enhance stability (not specified for this item)
  • Sense and antisense strands, with antisense guiding RISC to CSF2RA mRNA
• 2D conceptual description: Two antiparallel single-stranded RNA oligomers, partially complementary, annealed to form a short A-form duplex with characteristic minor/major groove geometry.

Note: Definitive sequence(s), modification pattern, and exact composition are item-specific and should be confirmed on the current CoA/Spec Sheet.

Synthetic Utility

As a biological knockdown reagent, this siRNA set is not a synthetic building block or catalyst and is not used in traditional organic synthesis.

• Utility in research workflows:
  • Functions as a tool compound for perturbing gene expression, enabling mechanism-of-action studies, pathway mapping, and validation of phenotypes prior to genome editing or overexpression studies.
  • Can be paired with small-molecule modulators to delineate on-target vs off-target effects through epistasis-like analyses.
• Methodological complementarity:
  • Complements CRISPRi/CRISPR knockout and antisense oligonucleotides; siRNA affords transient, titratable reduction of target mRNA, useful where permanent gene disruption is undesirable.

No conventional reaction transformations apply.

Target Specificity

• Target: Human CSF2RA (colony stimulating factor 2 receptor alpha subunit)
• Species reactivity: Designed for human transcripts. Cross-reactivity with non-human orthologs is sequence-dependent and not specified.
• Design: Pre-designed siRNA set A; exact sequences, number of duplexes, and modification patterns are not specified for this item. Consult CoA/Spec Sheet for definitive details.
• Selectivity considerations (general):
  • Use of multiple independent siRNAs and/or pooled siRNA reduces the impact of individual off-target interactions.
  • Validate on-target effects via mRNA/protein assays and, where feasible, rescue experiments.

No antibody clone/isotype or epitope data apply to this nucleic acid reagent.